[go: up one dir, main page]

PE20011122A1 - DERIVADOS DE PURINA-2-ILCARBOXAMIDA COMO AGONISTAS SELECTIVOS DEL RECEPTOR A2a DE LA ADENOSINA - Google Patents

DERIVADOS DE PURINA-2-ILCARBOXAMIDA COMO AGONISTAS SELECTIVOS DEL RECEPTOR A2a DE LA ADENOSINA

Info

Publication number
PE20011122A1
PE20011122A1 PE2001000174A PE2001000174A PE20011122A1 PE 20011122 A1 PE20011122 A1 PE 20011122A1 PE 2001000174 A PE2001000174 A PE 2001000174A PE 2001000174 A PE2001000174 A PE 2001000174A PE 20011122 A1 PE20011122 A1 PE 20011122A1
Authority
PE
Peru
Prior art keywords
alkyl
purine
phenyl
ilcarboxamide
adenosine
Prior art date
Application number
PE2001000174A
Other languages
English (en)
Inventor
Simon John Mantell
Peter Thomas Stephenson
Sandra Marina Monaghan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20011122A1 publication Critical patent/PE20011122A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)

Abstract

SE REFIERE A COMPUESTOS DE PURINA-2-ILCARBOXAMIDA DONDE R1 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C7, CON OH, FENILO, NAFTILO, ENTRE OTROS; A ES UN ENLACE O ALQUILENO C1-C6; R2 ES a) H, ALQUILO C1-C6, CICLOALQUILO C3-C7, FENILO CON ALQUILO C1-C6, (ALCOXI C1-C6)(ALQUILO C1-C6), ENTRE OTROS, CON LA CONDICION DE QUE CUANDO A ES UN ENLACE R2 NO ES H; b) CUANDO A ES ALQUILENO C2-C6, NR3R3, OR3, COOR3; c) HETEROCICLO DE 4-11 MIEMBROS, ENTRE OTROS; R3 ES H, ALQUILO C1-C6, FENILO, PIRIDINILO; R7 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C7, FENILO, NAFTILO, AZETIDIN-3-ILO, ENTRE OTROS; R8 ES H, ALQUILO C1-C6. SON COMPUESTOS PREFERIDOS 6-[(2,2-DIFENILETIL)AMINO]-9-{(2R,3R,4S,5S)-5-[(ETILAMINO)CARBONIL]-3,4-DIHIDROXITETRAHIDRO-2-FURANIL}-N-(2-PIRIDINILMETIL)-9H-PURINA-2-CARBOXAMIDA, N-BENCIL-6-[(2,2-DIFENILETIL)AMINO]-9-{(2R,3R,4S,5S)-5-[(ETILAMINO)CARBONIL]-3,4-DIHIDROXITETRAHIDRO-2-FURANIL}-9H-PURINA-2-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA, UN PROCEDIMIENTO PARA LA PREPARACION Y A COMPUESTOS INTERMEDIOS. EL COMPUESTO DE FORMULA I ES UN AGONISTA DEL RECEPTOR A2a DE LA ADENOSINA Y ACTUA COMO AGENTE ANTIINFLAMATORIO
PE2001000174A 2000-02-18 2001-02-16 DERIVADOS DE PURINA-2-ILCARBOXAMIDA COMO AGONISTAS SELECTIVOS DEL RECEPTOR A2a DE LA ADENOSINA PE20011122A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0003960.2A GB0003960D0 (en) 2000-02-18 2000-02-18 Purine derivatives

Publications (1)

Publication Number Publication Date
PE20011122A1 true PE20011122A1 (es) 2001-11-06

Family

ID=9886026

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000174A PE20011122A1 (es) 2000-02-18 2001-02-16 DERIVADOS DE PURINA-2-ILCARBOXAMIDA COMO AGONISTAS SELECTIVOS DEL RECEPTOR A2a DE LA ADENOSINA

Country Status (39)

Country Link
US (1) US6525032B2 (es)
EP (1) EP1255764B8 (es)
JP (1) JP2004508284A (es)
KR (1) KR20030036138A (es)
CN (1) CN1400975A (es)
AP (1) AP2002002598A0 (es)
AR (1) AR027437A1 (es)
AT (1) ATE325807T1 (es)
AU (1) AU2001230440A1 (es)
BG (1) BG106906A (es)
BR (1) BR0108408A (es)
CA (1) CA2400619A1 (es)
CO (1) CO5271668A1 (es)
CR (1) CR6722A (es)
CZ (1) CZ20022703A3 (es)
DE (1) DE60119492T2 (es)
EA (1) EA004987B1 (es)
EE (1) EE200200452A (es)
ES (1) ES2260199T3 (es)
GB (1) GB0003960D0 (es)
GT (1) GT200100027A (es)
HN (1) HN2001000027A (es)
HR (1) HRP20020676A2 (es)
HU (1) HUP0301055A2 (es)
IL (1) IL150543A0 (es)
IS (1) IS6458A (es)
MA (1) MA26873A1 (es)
MX (1) MXPA02008068A (es)
NO (1) NO20023894L (es)
NZ (1) NZ519971A (es)
OA (1) OA12177A (es)
PA (1) PA8511801A1 (es)
PE (1) PE20011122A1 (es)
PL (1) PL357220A1 (es)
SK (1) SK11692002A3 (es)
SV (1) SV2002000317A (es)
TN (1) TNSN01028A1 (es)
WO (1) WO2001060835A1 (es)
ZA (1) ZA200206526B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US6753322B2 (en) * 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
AU2002362443B2 (en) * 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
GB0129270D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Pharmaceutical combination
GB0129397D0 (en) * 2001-12-07 2002-01-30 Pfizer Ltd Pharmaceutical combination
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2005117910A2 (en) * 2004-05-26 2005-12-15 Inotek Pharmaceuticals Corporation Purine derivatives as adenosine a1 receptor agonists and methods of use thereof
US7442687B2 (en) * 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) * 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
JP5011112B2 (ja) * 2004-09-20 2012-08-29 イノテック ファーマシューティカルズ コーポレイション プリン誘導体を含有する炎症性疾患の治療用医薬
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
PL2532679T3 (pl) 2005-10-21 2017-09-29 Novartis Ag Ludzkie przeciwciała przeciwko IL13 i zastosowania terapeutyczne
AU2006320578B2 (en) * 2005-11-30 2013-01-31 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20080027022A1 (en) * 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
BRPI0710573A2 (pt) * 2006-04-21 2012-02-28 Novartis Ag compostos orgánicos, usos e processos para a preparação dos referidos compostos, bem como composição farmacêutica compreendendo os mesmos
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CN101516885A (zh) 2006-09-29 2009-08-26 诺瓦提斯公司 作为pi3k脂质激酶抑制剂的吡唑并嘧啶类化合物
WO2008052734A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
WO2008133129A1 (ja) * 2007-04-16 2008-11-06 Santen Pharmaceutical Co., Ltd. アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
EP2231642B1 (en) 2008-01-11 2013-10-23 Novartis AG Pyrimidines as kinase inhibitors
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
JP2012516345A (ja) 2009-01-29 2012-07-19 ノバルティス アーゲー 星細胞腫治療用置換ベンゾイミダゾール
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
SG10201404886PA (en) 2009-08-17 2014-10-30 Intellikine Llc Heterocyclic compounds and uses thereof
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
PH12012501320A1 (en) 2010-01-11 2013-01-21 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
EA201290958A1 (ru) 2010-03-26 2013-04-30 Инотек Фармасьютикалз Корпорейшн Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
PH12013501758A1 (en) 2011-02-25 2013-10-14 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
LT2807178T (lt) 2012-01-26 2017-08-25 Inotek Pharmaceuticals Corporation (2r,3s,4r,5r)-5-(6-(ciklopentilamino)-9h-purin-9-il)-3,4-dihidroksitetrahidrofuran-2-il) } metilnitrato bevandeniai polimorfai ir jų gavimo būdai
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
SG11201506882YA (en) 2013-03-15 2015-09-29 Inotek Pharmaceuticals Corp Ophthalmic formulations
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10940150B2 (en) 2014-07-28 2021-03-09 Technische Universitaet Dresden Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
TWI856342B (zh) * 2015-03-13 2024-09-21 瑞典商杜比國際公司 音訊處理單元、用於將經編碼的音訊位元流解碼之方法以及非暫態電腦可讀媒體
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140015A (en) * 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5189027A (en) * 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
CA2347512C (en) * 1998-10-16 2005-12-06 Pfizer Inc. Adenine derivatives
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
AP2002002598A0 (en) 2002-09-30
AU2001230440A1 (en) 2001-08-27
IL150543A0 (en) 2003-02-12
DE60119492T2 (de) 2006-11-09
NO20023894D0 (no) 2002-08-16
NZ519971A (en) 2004-04-30
JP2004508284A (ja) 2004-03-18
HRP20020676A2 (en) 2004-12-31
IS6458A (is) 2002-07-05
NO20023894L (no) 2002-10-01
PA8511801A1 (es) 2002-02-21
ZA200206526B (en) 2003-10-16
CA2400619A1 (en) 2001-08-23
OA12177A (en) 2006-05-09
BG106906A (en) 2003-04-30
KR20030036138A (ko) 2003-05-09
US20010020089A1 (en) 2001-09-06
EP1255764A1 (en) 2002-11-13
EA004987B1 (ru) 2004-10-28
HUP0301055A2 (hu) 2003-08-28
SV2002000317A (es) 2002-07-16
CZ20022703A3 (cs) 2003-09-17
AR027437A1 (es) 2003-03-26
CN1400975A (zh) 2003-03-05
ATE325807T1 (de) 2006-06-15
PL357220A1 (en) 2004-07-26
TNSN01028A1 (fr) 2005-11-10
SK11692002A3 (sk) 2003-11-04
WO2001060835A8 (en) 2001-11-29
CO5271668A1 (es) 2003-04-30
MXPA02008068A (es) 2004-04-05
GB0003960D0 (en) 2000-04-12
EE200200452A (et) 2003-12-15
EP1255764B1 (en) 2006-05-10
MA26873A1 (fr) 2004-12-20
ES2260199T3 (es) 2006-11-01
BR0108408A (pt) 2002-11-26
HN2001000027A (es) 2001-09-11
EA200200770A1 (ru) 2002-12-26
GT200100027A (es) 2001-12-19
CR6722A (es) 2003-11-25
US6525032B2 (en) 2003-02-25
EP1255764B8 (en) 2006-06-28
WO2001060835A1 (en) 2001-08-23
DE60119492D1 (de) 2006-06-14

Similar Documents

Publication Publication Date Title
PE20011122A1 (es) DERIVADOS DE PURINA-2-ILCARBOXAMIDA COMO AGONISTAS SELECTIVOS DEL RECEPTOR A2a DE LA ADENOSINA
PE20011269A1 (es) DERIVADOS DE 9-(5-HETEROARILTETRAHIDROFURANIL)-PURINA COMO AGONISTAS SELECTIVOS DEL RECEPTOR A2a DE LA ADENOSINA
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
SV2003000697A (es) Agonistas del receptor beta3-adrenergico y usos de los mismos ref. pc11008/700016/bb
TR200201001T2 (tr) Pürin türevleri
RU95106649A (ru) Производные бензимидазола в качестве непептидильных антагонистов рецепторов тахикинина, способ получения, фармацевтическая композиция
AR030045A1 (es) Composicion farmaceutica que contiene compuestos antibioticos de azalida , metodos para obtencion
TR200103607T2 (tr) Pürin Türevleri
TR200401622T4 (tr) Pürin türevleri
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
PE20020968A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada
PE20010126A1 (es) Pirrolotriazinas como inhibidores de cinasas
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
PE20040499A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
AR028816A1 (es) "n-alcoxiaminas impedidas sustituidas con hidroxi, composicion, proceso para estabilizar un polimero organico o material de registro contra los danos producidos por la luz, el oxigeno y/o el calor, y proceso para preparar las n-alcoxiaminas.
ATE361667T1 (de) Stoppen, schützen und konservieren von organen
SV2002000969A (es) Composicion parenteral reconstituible
AR040021A1 (es) (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetrahidrofuril-carbonil)-4-piperidinilmetil]-4-piperidinil]benzamida, procedimiento para su preparacion, composicion farmaceutica que la contiene, e intermediarios para su preparacion
PE20020348A1 (es) Exemestano como agente quimiopreventivo
AR023807A1 (es) Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
PE3096A1 (es) Formulacion conteniendo selenio
ES2090083T3 (es) Derivados de cefalosporina, procedimiento para su preparacion y composicion antimicrobiana que contiene estos derivados.
AR031649A1 (es) Composicion farmaceutica de dronedarona para administracion parenteral
PE107599A1 (es) Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h)-tiofenonas como agentes antitumorales

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed